Unknown

Dataset Information

0

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.


ABSTRACT: The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors). This review will focus on ixazomib, an orally bioavailable second-generation proteasome inhibitor. Specifically, we will review the preclinical data, clinical trial experience, potential indications as well as unanswered questions pertaining to this new agent in multiple myeloma.

SUBMITTER: Brayer J 

PROVIDER: S-EPMC5495505 | biostudies-other | 2017 Jul

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC10225187 | biostudies-literature
| S-EPMC9107792 | biostudies-literature
| S-EPMC8827146 | biostudies-literature
| S-EPMC7072336 | biostudies-literature
| S-EPMC7922145 | biostudies-literature
| S-EPMC8840911 | biostudies-literature
| S-EPMC10046772 | biostudies-literature
| S-EPMC8323061 | biostudies-literature
| S-EPMC4279864 | biostudies-literature